Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

TransMedics (OCS) Liver Trial: Preserving and Assessing Donor Livers for Transplantation (Liver PROTECT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02522871
Recruitment Status : Active, not recruiting
First Posted : August 13, 2015
Last Update Posted : January 29, 2020
Sponsor:
Information provided by (Responsible Party):
TransMedics

Brief Summary:
A prospective, phased-pivotal, international randomized trial to evaluate the effectiveness of the OCS™ Liver to preserve and assess donor livers intended for transplantation.

Condition or disease Intervention/treatment Phase
Liver Transplantation Liver Preservation for Transplant Device: OCS™ Liver System Other: Control Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: International Randomized Trial to Evaluate The Effectiveness of The Portable Organ Care System (OCS™) Liver For Preserving and Assessing Donor Livers for Transplantation (OCS Liver PROTECT Trial)
Study Start Date : January 2016
Actual Primary Completion Date : October 22, 2019
Estimated Study Completion Date : December 2020

Arm Intervention/treatment
Experimental: OCS Liver System
OCS Liver System
Device: OCS™ Liver System
Control
Standard of care (ice)
Other: Control



Primary Outcome Measures :
  1. Incidence of Early Liver Allograft Dysfunction (EAD) [ Time Frame: 7 days ]
  2. Incidence of liver graft related Serious Adverse Events (SAEs) [ Time Frame: 30 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Registered male or female primary Liver transplant candidate
  • Age ≥18 years old
  • Signed: 1) written informed consent document and 2) authorization to use and disclose protected health information

Exclusion Criteria:

  • Acute, fulminant liver failure
  • Prior solid organ or bone marrow transplant
  • Chronic use of hemodialysis or diagnosis of chronic renal failure, defined as chronic serum creatinine of >3 mg/dl for >2 weeks and/or requiring hemodialysis
  • Multi-organ transplant
  • Ventilator dependent
  • Dependent on > 1 IV inotrope to maintain hemodynamics

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02522871


Locations
Show Show 20 study locations
Sponsors and Collaborators
TransMedics
Layout table for additonal information
Responsible Party: TransMedics
ClinicalTrials.gov Identifier: NCT02522871    
Other Study ID Numbers: OCS-LVR-092014
First Posted: August 13, 2015    Key Record Dates
Last Update Posted: January 29, 2020
Last Verified: January 2020